-
05 Robert LaCaze-拜耳全球肿瘤研发及业务新方向
Robert LaCaze 总裁拜耳全球肿瘤事业部总裁Robert LaCaze is a senior bio-pharmaceutical executive with more than 28 years of experience in the industry. Throughout his career he has served in multiple operational and strategic roles involving the US, EU, China and Japan.Mr. LaCaze joined Bayer Pharmaceuticals in October 2015 and currently serves as the Executive Vice President and Head of the Oncology Strategic Business Unit (SBU). The Oncology SBU is responsible for all strategy in Bayer’s Oncology Business and consists of: Clinical Development, Regulatory Affairs, Strategic Medical Affairs, Strategic Marketing and Commercialization, Oncology Market Access and Clinical Operations. He is also a member of Bayer’s Pharmaceutical Executive Committee.Prior to joining Bayer, Mr. LaCaze spent over 25 years with Bristol Myers Squibb serving in multiple roles including his two most recent roles of Senior Vice President and Head of Product and Portfolio Strategy for Worldwide Commercialization and Senior Vice President, Global Oncology Commercialization in which he was responsible, with his R&D counterpart, for setting the vision and strategy for the Immuno-Oncology (I-O) franchise. He oversaw the early strategy for Nivolumab and lead the Global Launch of Ipilimumab BMS’s first I-O drug and the Global launch of BMS’s first target therapy, Dasatinib. Both of which have achieved more than $1B in annual sales.Mr LaCaze is a member of AACR and also serves as a member of the College of Business Advisory Board for Louisiana Tech University, his alma mater. He, his wife, and two sons reside in Robbinsville NJ.
2018-04-05 45415 看过 免费 -
03 韩国宏-介入新思路：建立 TACE 技术与靶向药物治疗最佳联合
韩国宏 教授空军军医大学（第四军医大学）西京医院消化介入科主任主任医师、教授、博导亚太原发性肝癌理事会理事（APPLE Council Member）中华医学会放射学分会介入学组副主任委员中国研究型医院学会介入专委会副主任委员中华医学会消化学分会介入协作组副组长卫计委原发性肝癌诊疗规范专家委员会委员（2011 版和 2017 版）2017 年以第一完成人获军队科技进步一等奖2016 年作为主要成员获国家科学进步奖创新团队奖2012 年至 2016 年连续五年荣登中国名医百强榜（介入放射治疗科）2010 年以来作为第一或通讯作者在 Gut、Nat Rev Gastro & Hepatol 、 Hepatology 、 J Hepatol 、 Ann Oncol 、 Clin Cancer Res 、 Radiology、 Thromb & Haemost 等权威杂志发表 SCI 同行评议论文 129 篇
2018-04-05 85311 看过 免费
热门资讯
- 李丹教授：从临床实践及循证医学证据看——重症ILD如何使用糖皮质激素和抗纤维化药物
- 减重新药解读！新一代偏向型GLP-1到底偏向哪里？机制与疗效有何不同？
- 李丹教授：糖皮质激素和抗纤维化药物治疗重症间质性肺炎的作用机制
- 罗红教授：下呼吸道病原学的精准治疗——mNGS与tNGS该如何选择应用时机？
- 李国强教授：血液灌流治疗脓毒症的应用探讨——目标人群
- 余跃天教授：blaKPC基因突变体——耐药机制、危害与临床应对策略
- 春日远离新冠重症与长新冠，这5点一定要记牢
- 从指南到实践：超重/肥胖合并高尿酸血症如何破局？新一代偏向型GLP-1RA带来新机遇
- 新春守护，安心同行：老年人及高风险人群新冠防护与抗病毒治疗全攻略
- 0601-领航计划—皮肤科高质量发展先锋行动项目第六季第42期
